MGP Inhibitors
MGP inhibitors encompass a range of chemicals that indirectly affect the function or activity of Matrix Gla Protein (MGP), primarily through pathways associated with Vitamin K-dependent carboxylation or cellular processing of proteins. The majority of these inhibitors operate by antagonizing Vitamin K, a crucial cofactor for the carboxylation and activation of MGP. Compounds like Warfarin, Coumadin, Acenocoumarol, and Dicoumarol inhibit the Vitamin K epoxide reductase complex, reducing the availability of Vitamin K for MGP carboxylation. This reduction in carboxylation directly impacts MGP's ability to inhibit vascular calcification, a key function of the protein in maintaining vascular health.
Other compounds, including Chloroquine, Hydroxychloroquine, Amitriptyline, Imatinib, Cladribine, and Bortezomib, modulate cellular pathways such as lysosomal function, autophagy, cellular signaling, nucleotide metabolism, and protein degradation. These pathways are essential for the proper processing and function of various proteins, including MGP. By influencing these pathways, these compounds can indirectly lead to decreased MGP activity, affecting its role in disrupting vascular calcification. In summary, MGP inhibitors are characterized by their indirect actions on the pathways crucial for MGP's activation and function. These inhibitors play a significant role in modulating MGP, primarily through the Vitamin K-dependent carboxylation pathway or by affecting cellular processes essential for protein maturation and function. Their impact on MGP highlights the intricate interplay between vitamin metabolism, cellular processing pathways, and protein function in biological systems.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Warfarin | 81-81-2 | sc-205888 sc-205888A | 1 g 10 g | $73.00 $246.00 | 7 | |
Warfarin is a Vitamin K antagonist that inhibits the Vitamin K epoxide reductase complex. This inhibition prevents the recycling of Vitamin K, crucial for the carboxylation of MGP. Inadequate carboxylation of MGP due to reduced Vitamin K availability can lead to decreased functionality of MGP, thus inhibiting its ability to prevent vascular calcification. | ||||||
Acenocoumarol | 152-72-7 | sc-217560 | 25 mg | $191.00 | 1 | |
Acenocoumarol functions as a Vitamin K antagonist, similar to Warfarin, by inhibiting Vitamin K epoxide reductase. This inhibition results in decreased Vitamin K recycling, reducing the availability of Vitamin K for the carboxylation of MGP, thus indirectly inhibiting MGP's function. | ||||||
Dicoumarol | 66-76-2 | sc-205647 sc-205647A | 500 mg 5 g | $20.00 $40.00 | 8 | |
Dicoumarol, another Vitamin K antagonist, inhibits Vitamin K epoxide reductase. By reducing the recycling of Vitamin K, it indirectly inhibits the carboxylation and subsequent activation of MGP, impacting its role in preventing vascular calcification. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine, an antimalarial drug, can affect lysosomal function and cellular autophagy pathways. By modulating these pathways, Chloroquine can indirectly influence the cellular processing and maturation of proteins, including MGP, potentially leading to reduced functional MGP activity. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $57.00 | 1 | |
Hydroxychloroquine, similar to Chloroquine, can modulate lysosomal function and autophagy. This modulation may impact the processing and function of proteins like MGP, potentially leading to an indirect inhibition of its activity. | ||||||
Amitriptyline Hydrochloride | 549-18-8 | sc-210801 | 1 g | $200.00 | ||
Amitriptyline Hydrochloride can affect lysosomal acidification and autophagic processes. These alterations can influence the cellular processing and function of MGP, potentially leading to reduced effectiveness in inhibiting vascular calcification. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib, a tyrosine kinase inhibitor, can influence cellular signaling pathways and affect protein processing. Its impact on these pathways may indirectly inhibit the activation and function of MGP, particularly in the context of vascular biology. | ||||||
2-Chloro-2′-deoxyadenosine | 4291-63-8 | sc-202399 | 10 mg | $144.00 | 1 | |
2-Chloro-2′-deoxyadenosine can alter nucleotide metabolism and affect cellular signaling pathways. These alterations can influence the expression and functionality of proteins like MGP, potentially leading to its indirect inhibition. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, can affect protein degradation pathways. By influencing these pathways, Bortezomib can indirectly impact the stability and function of MGP, potentially inhibiting its role in vascular calcification prevention. | ||||||